Firefly Neuroscience (AIFF) Stock Price, News & Analysis

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (AI) company in the technology sector that develops neuroscientific software applications aimed at improving brain health outcomes for patients with neurological and mental disorders. According to the company’s public disclosures, Firefly focuses on commercializing its FDA‑510(k) cleared Brain Network Analytics (BNA™) technology and related platforms that analyze electroencephalogram (EEG) and event‑related potential (ERP) data. The company reports one primary operating segment centered on its BNA platform and derives revenue from North America.

Firefly’s technology uses AI and machine learning to interpret standardized, high‑definition longitudinal EEG and cognitive EEG (ERP) recordings. These analytics are designed to provide clinicians and researchers with insights into brain function that can support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. The company states that BNA, when used with an FDA‑cleared EEG/ERP system, can help clinicians assess which therapy or drug may be best suited to optimize a patient’s outcome.

Over more than a decade, Firefly has built an extensive proprietary database of brain wave tests. Company materials describe this as the world’s largest known standardized EEG/ERP repository, with more than 180,000 EEG/ERP assessment records and a normative reference group that includes over 17,000 patients across twelve disorders as well as clinically normal individuals. This database underpins the BNA platform and supports biomarker discovery, cognitive profiling, and longitudinal monitoring of brain function.

Core technology and platforms

The company’s flagship technology is its FDA‑510(k) cleared Brain Network Analytics (BNA™) platform. BNA was developed using AI and machine learning applied to Firefly’s proprietary EEG/ERP datasets. In conjunction with an FDA‑cleared EEG or EEG/ERP system, BNA processes brain activity recorded at rest and during cognitive tasks, then compares those patterns to age‑matched normative data. The resulting analytics provide measures of functional brain networks and cognitive performance that can be used as objective indicators of mental and cognitive status.

Firefly has also introduced its CLEAR (CLeaning EEG ARtifacts) Platform, described as a proprietary next‑generation preprocessing technology designed to improve EEG data quality. CLEAR uses signal processing and machine learning techniques to reduce artifacts such as muscle activity, eye blinks, and environmental interference. Company announcements state that CLEAR was developed using NVIDIA’s L40S GPU with Ada Lovelace architecture and that internal validation showed substantial increases in data quality and processing speed, which support more reliable biomarker detection and scalable analysis across the company’s EEG/ERP repository.

Data assets, intellectual property, and acquisitions

Firefly reports that it has built its database of standardized EEG/ERP assessments over many years of clinical studies and clinical assessments. In connection with its acquisition of Evoke Neuroscience, Inc., a medical device company focused on technologies for comprehensive assessment of brain health, Firefly disclosed that its assets and business now include a proprietary database of more than 180,000 standardized EEG/ERP assessment records, 27 granted patents, and more than 60 commercial users of its technology. The company characterizes these increases as multi‑fold expansions of its database, intellectual property portfolio, and commercial footprint.

The Evoke acquisition also expanded the company’s commercial base and contributed to growth in EEG/ERP scan volumes and revenue, as described in Firefly’s financial results. Firefly has indicated that the integration of Evoke’s business and data is an important step toward its stated goal of building an EEG/ERP‑based foundation model of the human brain using its BNA technology.

Commercial focus and customer groups

Firefly describes its commercial strategy as centered on licensing and deploying its BNA platform and related EEG‑based analytics to both research and clinical customers. Public statements indicate that the company targets pharmaceutical and medtech organizations involved in drug research and clinical trials, where objective measures of brain activity can serve as endpoints or exploratory measures. Firefly also targets medical practitioners and clinics for clinical use of its platform in diagnostic and treatment‑monitoring workflows.

The company has highlighted collaborations with academic medical centers and industry partners. For example, Firefly is commercially engaged with the Institute of Human Genetics at Heidelberg University Hospital in a study investigating the neurophysiological impact of 15q13.3 copy number variants, providing EEG systems, training, and full analytic support through its BNA platform and normative database. Firefly has also partnered with Hemostemix Inc. to use BNA as an exploratory endpoint in a Phase 1 vascular dementia clinical trial and with HealingMaps and Advanced Behavioral Strategies to offer EEG‑based, AI‑driven brain health analytics to a large network of ketamine, psilocybin, and transcranial magnetic stimulation (TMS) clinics across North America.

Applications in brain health and neuroscience

Across its communications, Firefly positions its technology as a way to transform complex brain data into objective, standardized measures that can support both clinical care and research. BNA assessments can be performed at rest and during visual and auditory cognitive tasks, generating functional brain measures that are compared against age‑matched normative ranges. These outputs are intended to help characterize cognitive function, detect deviations from expected patterns, and monitor changes over time.

The company cites applications in neuropsychiatric and neurodegenerative conditions, including depression, dementia, anxiety disorders, concussions, ADHD, and vascular dementia. Firefly has also highlighted research that combines EEG/ERP measures with volumetric MRI (vMRI) to differentiate subjective cognitive decline, mild cognitive impairment, and dementia in Alzheimer’s patients, and has referenced work on cognitive brain age biomarkers derived from its database.

Stock listing and corporate profile

Firefly Neuroscience, Inc. trades on the Nasdaq Stock Market under the ticker symbol AIFF and is classified in the Software – Application industry within the technology sector. The company has indicated that it is a member of the Russell Microcap® Index, placing it among smaller publicly traded U.S. companies by market capitalization. Firefly’s corporate headquarters mailing address in SEC filings is in Kenmore, New York.

As a public company, Firefly files annual reports, quarterly reports, current reports, and proxy statements with the U.S. Securities and Exchange Commission (SEC). These filings provide information on its business, risk factors, financial condition, governance, and shareholder matters, including details about its long‑term incentive plan and authorized share structure.